Daclatasvir

26 interactions 3 explained in plain English

Also sold as: Daklinza®

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Colchicine Abametapir Dexamethasone Ophthalmic Alpelisib Nifedipine Ketoconazole Topical

1 Contraindicated 22 Major 3 Moderate

All (26) Contraindicated (1) Major (22) Moderate (3)

Contraindicated

Daclatasvir Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details

Major

Daclatasvir Abametapir Explained Increased exposure of CYP3A4 substrate Details Daclatasvir Relugolix Orgovyx Explained Increased relugolix exposure Details Daclatasvir Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Daclatasvir Atogepant Qulipta Increased atogepant exposure Details Daclatasvir Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Daclatasvir Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Daclatasvir Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Daclatasvir Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Daclatasvir Dexamethasone Injection Decadron Decreased daclatasvir exposure and risk of loss of daclatasvir efficacy Details Daclatasvir Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Decreased daclatasvir exposure and risk of loss of daclatasvir efficacy Details Daclatasvir Digoxin Cardoxin® Increased digoxin exposure Details Daclatasvir Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Daclatasvir Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Daclatasvir Ketoconazole Topical Extina® Foam Increased daclatasvir exposure Details Daclatasvir Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Daclatasvir Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Daclatasvir Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Daclatasvir Methylergonovine Methergine Increased methylergonovine exposure Details Daclatasvir Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Daclatasvir Nafcillin Injection Unipen® Injection Decreased daclatasvir exposure and risk of loss of daclatasvir efficacy Details Daclatasvir Nevirapine Viramune Decreased daclatasvir exposure and risk of loss of daclatasvir efficacy Details Daclatasvir Nifedipine Adalat® Increased NIFEdipine exposure Details

Moderate

Daclatasvir Dofetilide Tikosyn Increased dofetilide exposure Details Daclatasvir Hydrocortisone Ala-Cort Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Daclatasvir Hydrocortisone Injection A-Hydrocort® Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.